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Nardo JM van der Meer5Abstract
We describe a patient with acute cardiogenic shock due to cardiac involvement in idiopathic hypereosinophilic
syndrome (Löffler endocarditis). At the echocardiography, there was a huge mass in the left ventricular cavity,
resulting in inflow- and outflow tract obstruction. The posterior leaflet of the mitral valve apparatus was completely
embedded in a big (organized) thrombus mass. The patient was treated with high dose corticosteroids, however
without effect. Partial remission was achieved after treatment with hydroxycarbamide. He was also treated with
anticoagulants and high dose beta-blockers. The patient’s condition improved remarkably after correction of the
mitral valve insufficiency by a mitral valve bioprosthesis.
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The hypereosinophilic syndromes (HES) are a heterogenous
group of disorders marked by the sustained overproduction
of eosinophils. It is a rare condition with an unknown
prevalence. Diagnosis is based on three criteria: (1) an
eosinophil count of more than 1500 cells per microliter for
at least 6 months, (2) no other evident cause for eosino-
philia, including allergic diseases and parasitic infection and
(3) sign or symptoms of organ involvement by eosinophilic
infiltration [1]. Cardiac involvement is common in HES and
eosinophilic myocarditis is a major cause of morbidity and
mortality among patients with HES. Mitral valve invol-
vement may lead to acute cardiac failure. We present a
patient with idiopathic hypereosinophilic syndrome and
severe cardiac involvement, so-called Löffler endocarditis.
Case report
A 37-year-old male patient presented to the emergency
department with one month of fatigue and five days of
progressive dyspnoea and fever. Three months earlier he
had been diagnosed with idiopathic hypereosinophilia.
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reproduction in any medium, provided the orneither a cause for secondary eosinophilia nor any car-
diac abnormalities. Oral prednisone was given for two
months, but was gradually tapered since there was no
decline in eosinophil count.
On admission we saw an acutely ill-looking man,
temperature 38.1°C, blood pressure 80/47 mmHg, heart
rate 137 beats/min and a saturation of 90% with 15 liters
per minute of oxygen therapy by a non-rebreathing
mask. Auscultation of the heart revealed no murmurs;
diffuse inspiratory crackles were heard during
ausculation of the lungs. No other abnormalities were
found. Laboratory evaluation revealed a white blood cell
count of 96.8 × 109/L, of which 84.2 × 109/l were eosi-
nophils (87%), hemoglobin 8.6 mmol/l, thrombocytes
238 × 109/L, C-reactive protein 122 mg/L, creatinine
141 umol/L, lactate dehydrogenase 426 U/L, aspartate
aminotransferase 28 U/L and creatine phosphokinase 45
U/L. Arterial blood gas analysis showed a pH of 7.46,
pCO2 4.3 kPa, pO2 8.5 kPa and bicarbonate 23 mmol/L.
Chest X-ray showed bilateral pulmonary congestion. The
electrocardiogram showed a sinus tachycardia, a QS
complex in V1 and V2, 2 mm. ST-elevations in V1-V3
and ST-depressions in II, III, AVF, V5 and V6 (Figure 1).
Transthoracic echocardiography revealed a large mass in
the left ventricle (LV) attached to the posterolateral wall
with severe inflow- and outflow tract obstruction; echo
Doppler maximal LV outflow tract velocity was 6 m/sral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Electrocardiogram at admission showing a sinusrythm with ST-elevations in V1-V3 and ST-depressions in II, III, AVF, V5 and V6.
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(PMVL) was completely embedded in the mass. The left
and right ventricular function was however fully normal.
Because of progressive respiratory failure, the trachea was
intubated and mechanical ventilation was initiated. A CT-
scan of the thorax confirmed the large (thrombus) mass in
the left ventricle, left and right atrial dilatation, pulmonary
edema and bilateral pleural effusions. Cardiac magnetic res-
onance imaging (MRI) showed endomyocardial fibrosis and
necrosis and a large thrombus in the left ventricle with ob-
struction of the left ventricle outflow tract. A diagnosis of
Löffler endocarditis was made. Pharmacological therapy
was initiated with diuretics, high dose beta-blockers,
methylprednisolone (1000 mg a day for three days) and
anti-coagulation along with antiplatelet agents acetylsali-
cylic acid and clopidogrel. Mechanical ventilation was ne-
cessary for twelve days. After this period weaning and
extubation was successfully. Because of severe diastolic dys-
function with an inflow and outflow tract obstruction of
the left ventricle due to the thrombus, inotropics were not
helpful and patient received only on the first day norepin-
ephrine. Initially there was a marked decline in his eosino-
phil count (white blood cell count of 32 × 109/L with 17 ×
109/L eosinophils (53%) however this was of short duration.
Therefore we started therapy with interferon alpha and
hydroxycarbamide resulting in a gradual decline of the eo-
sinophil count (white blood cell count of 6.6 × 109/L, of
which 2.28 × 109/L (34.5%) were eosinophils). Signs of bone
marrow depression with anemia and thrombocytopenia
complicated this therapy. Interferon alpha therefore was
stopped.
Two months later the cardiac MRI was repeated and
still showed the large mass in the left ventricle but with a
25% decline. During follow-up at four months there was
persistent heart failure, New York Heart Association Class
III to IV. Echocardiography showed also a severe mitralregurgitation because the posterior mitral valve leaflet was
embedded in the thrombus mass (Figure 3A and B) and a
severe secondary pulmonary hypertension (estimated pul-
monary artery systolic pressure 60 to 65 mm Hg). In a
multidisciplinary team discussion we concluded that mi-
tral valve replacement was the only option for this young
patient with severe heart failure. A surgical correction of
the mitral regurgitation was performed through ster-
notomy. A mitral valve bioprosthesis was inserted. After
this operation the patient recuperated well, although the
eosinophilia persisted (white blood cell count of 12 × 109/
L, of which 85% were eosinophils). Therefore, interferon
alpha was added again to the therapy with hydroxycarba-
mide. However, high doses were needed and patient devel-
oped again a pancytopenia. Additional treatment with
Imatinib (a tyrosine kinase inhibitor) and Mepolizumab
(a humanized monoclonal antibody against interleukin-5)
did not lead to a satisfactory further decrease in eosinophil
count. Eventually it was decided to perform an allogenic
stem cell transplantation. Apart from a mild to moderate
graft versus host reaction (GVHD), this procedure was un-
complicated. Currently, patient is doing well. After trans-
plantation his eosinophilic count is 1.24 × 109/L (20%). As
post transplantation chimerism analysis showed more
than 95% donor cells, the remaining eosinophilia is con-
sidered to be due to the GVHD.
Discussion
Acquired eosinophilia can be classified into secondary
(cytokine-driven reactive phenomenon), clonal (presence
of a bone marrow histological, cytogenetic or molecular
marker of a myeloid malignancy) and idiopathic (neither
secondary nor clonal) categories [2]. In 1975 Chusid et al.
described diagnostic criteria for idiopathic HES that re-
main in use today. These are blood eosinophilia of >1500
cells per microliter for more than six consecutive months,
Figure 2 A and B, Echocardiographic parasternal long axis view and four-chamber view at presentation, showing big thrombotic mass
with the base at the posterior wall and infiltration of the left ventricular wall.
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pite extensive diagnostic evaluation, and organ damage or
dysfunction as a result of local release of the toxic con-
tents of eosinophils [1]. HES affects mostly men between
20 and 50 years of age, with a peak in the 4th decade of life
[3,4]. There are no published data regarding its incidence/
prevalence, although the syndrome is considered rare in
adults and very rare in children.
The exact etiology of HES is unknown; however, the
process probably involves a dysregulation of IL-3, IL-5 and/
or GM-CSF, which are all eosinophil growth factors [3,5].
Clinical manifestations of HES are markedly heteroge-
neous as the disease can either be completely asymptomatic
or involve multiple organs. In essence, any organ isvulnerable to eosinophilia-associated tissue damage.
Thromboembolic disease involving the cardiac chambers
and/or both the venous and arterial vessels is not infre-
quent [2]. Cardiac involvement occurs in more than 75% of
patients with HES and is the major cause of morbidity and
mortality [6]. Cardiac involvement in HES usually follows
three stages. The first is an acute necrotic stage. This stage
is usually neither recognized clinically nor diagnosed, like
in our case. In this stage there is damage to the endocar-
dium and infiltration of the myocardium with eosinophils
and lymphocytes with histopathological evidence of myo-
cardial necrosis and eosinophil degranulation and eosino-
phil micro abscesses [3,7]. The second stage concerns
thrombosis with formation of thrombi along the damaged
Figure 3 A and B, Same view at 4 months of follow-up, demonstrating smaller but evidently present thrombotic mass, with embedded
posterior leaflet apparatus of the mitral valve, resulting in severe mitral regurgitation (not shown).
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ally in the atrium. Outflow tracts near the aortic and pul-
monic valves are usually spared, although rarely thrombus
may involve these valves and thrombus may form on atrio-
ventricular valve leaflets [3,8-10]. This stage is found in
those with a mean 10-month duration of eosinophilia [3].
In the third late fibrotic stage progressive scarring may lead
to entrapment of chordae tendineae resulting in mitral
and/or tricuspid valve regurgitation and endomyocardial fi-
brosis producing a restrictive cardiomyopathy [3].
To diagnose HES and Löffler endocarditis, echocardi-
ography enables sufficient detection of thickened endo-
cardium and intraventricular thrombus. Nevertheless,
acute necrotic stage can come along with absolutenormal echocardiographic findings [3]. Endomyocardial
thickening is seen in 68% of patients on echocardiog-
raphy and is progressive [11]. Apical thrombus in the
presence of normal apical contraction is one of the
main clues in suspected Löffler’s endomyocarditis [12].
There are three primary goals for the management of
HES: 1) reduction of peripheral and tissue levels of eosino-
phils; 2) prevention of end-organ damage; and 3) preven-
tion of thrombo-embolic events in patients at risk [13,14].
Patients without progressive organ system dysfunction
typically do not require specific treatment, however, these
patients should be monitored closely [14]. Corticosteroids
were initially the mainstay of HES treatment and are cur-
rently recommended as first-line therapy [15,16].
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subsets with corticosteroid resistance or when corticoster-
oid tapering is necessary [16]. Interferon-alpha is an immu-
nomodulator that reduces Th2-mediated IL-5 production,
synthesis of GM-CSF and release of eosinophil-specific
neurotoxin and eosinophil cationic protein and indirectly
inhibits eosinophil differentiation [5,13,17]. It is recom-
mended for use in HES patients with organ damage and
corticosteroid/cytotoxic treatment failure [17,18]. Allogenic
stem cell transplantation has also been reported to be a po-
tentially curative therapy. It is the ultimate therapeutic
measure in case of therapeutic refractoriness or intolerance
to available therapies or in patients who present with pro-
gressive life-threatening end-organ damage. The optimal
preparative regime is not well established and it is asso-
ciated with major morbidity and even mortality [19,20].
Several therapies are currently under investigation as poten-
tial HES therapies, like Mepolizumab, a fully humanized
monoclonal IgG anti-IL5 antibody. The secondary treat-
ment should be directed at cardiac complications, e.g., heart
failure and the presence of intracardial thrombus. In the
view of subclinical progression of the cardiac involvement,
especially in the primary stage of HES, our case suggests
very early and aggressive anticoagulation, regardless of the
initial (negative) cardiac evaluation. Occasionally, surgical
therapies are needed for cardiovascular complications. Sur-
gical experience of patients with valvular dysfunction sec-
ondary to HES is limited [21]. Valve replacement is most
often performed but the choice between a mechanical or
biological prosthesis in this setting poses a difficult problem.
Mechanical valves have a high incidence of recurrent ob-
structive thrombosis and therefor a bioprosthesis is recom-
mended despite associated restrictive cardiomyopathy [6].
Conclusions
Hypereosinophilic syndrome is a rare cause of cardiac
failure resulting in cardiogenic shock due to endom-
yocardial thickening and thrombus formation. Both
may impede left ventricular in- and outflow tract. The
risk increases when the duration of hypereosinophilia is
more than ten months. Besides first line therapy
(corticosteroids), early aggressive anticoagulation therapy
is warranted. In more severe cases acute surgical inter-
vention is necessary.Consent
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